Your browser doesn't support javascript.
loading
Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 524-533, 2022.
Article in Chinese | WPRIM | ID: wpr-939742
ABSTRACT
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or surgical issues for neoadjuvant immunotherapy in non-small cell lung cancer.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Carcinoma, Non-Small-Cell Lung / Neoadjuvant Therapy / Antineoplastic Agents, Immunological / Nivolumab / Immunotherapy / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Carcinoma, Non-Small-Cell Lung / Neoadjuvant Therapy / Antineoplastic Agents, Immunological / Nivolumab / Immunotherapy / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article